A clinical-stage biotechnology firm focused on developing new remedies for blinding eye diseases.

Acucela to provide data on ACU-4429 oral visual cycle modulator for dry out AMD at Retina International meeting Acucela, a clinical-stage biotechnology firm focused on developing new remedies for blinding eye diseases, today that Ryo Kubota announced, M.D., Ph meds online .D., Acucela’s chairman, president and chief executive officer, provides been invited to take part in Retina International’s annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010. During the event – which has been held in conjunction with the Association for Study in Eyesight and Ophthalmology’s 2010 Annual Meeting – select professionals will examine recent advancements in the treatment of degenerative retinal illnesses.

Food and Medication Administration for ACU-4429, an investigational oral treatment for dry age-related macular degeneration . Fast Track designated programs may be eligible for concern regulatory review by the FDA. By slowing this cycle, ACU-4429, in the preclinical studies, has demonstrated the ability to decrease the degrees of toxic by-products in the eye and thereby potentially end the advance of dry AMD. Dry AMD is a leading cause of vision reduction in people older than 50, yet there are no therapies approved to treat this condition currently.D., Ph.D., chairman, president and chief executive officer of Acucela. We anticipate advancing the ACU-4429 program, along with our strategic partner Otsuka Pharmaceutical, and offering ongoing updates to the experts, physicians and patients who eagerly are therefore searching for a secure and efficient treatment for dry AMD..